The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Diurnal Group plc

13 Sep 2022 08:32

RNS Number : 2490Z
Panmure Gordon (UK) Limited
13 September 2022
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Panmure Gordon (UK) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Diurnal Group PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

Diurnal Group PLC

(d) Date dealing undertaken:

12 Sep 2022

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

10p Ordinary

Purchase

 

140,125

0.2671

 

0.267

 

10p Ordinary

Sales

54,500

0.26824

 

0.26824

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing, or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

13/09/2022

Contact name:

Mohammed Jamal

Telephone number:

020 7886 2780

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERFZGMLNFMGZZG
Date   Source Headline
17th Sep 202012:40 pmEQSHardman & Co Research: Diurnal Group (DNL): Closely watching the regulators
15th Sep 20207:00 amRNSResults for the year ended 30 June 2020
11th Sep 20207:00 amRNSShares and AJ Bell Investor Evening Webinar
3rd Sep 20205:33 pmRNSHoldings in Company
3rd Sep 20207:00 amRNSTwo further marketing and distribution agreements
27th Aug 20207:00 amRNSRichard Ross receives honour by Endocrine Society
20th Aug 20207:15 amEQSHardman & Co Research: Diurnal Group (DNL): Q&A with Dr Martin Hall
19th Aug 202010:00 amRNSNotice of Full Year Results
13th Aug 20202:06 pmRNSSecond Price Monitoring Extn
13th Aug 20202:00 pmRNSPrice Monitoring Extension
13th Aug 20207:15 amEQSHardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals
10th Aug 20209:14 amRNSHolding(s) in Company
10th Aug 20207:00 amRNSAlkindi approved in Australia
5th Aug 20207:00 amRNSAlkindi approved in Israel
30th Jul 20204:41 pmRNSSecond Price Monitoring Extn
30th Jul 20204:35 pmRNSPrice Monitoring Extension
30th Jul 20202:06 pmRNSSecond Price Monitoring Extn
30th Jul 20202:00 pmRNSPrice Monitoring Extension
30th Jul 202011:05 amRNSSecond Price Monitoring Extn
30th Jul 202011:00 amRNSPrice Monitoring Extension
30th Jul 20207:01 amRNSBusiness and trading update
30th Jul 20207:00 amRNSPositive DITEST Regulatory Meeting with US FDA
29th Jul 20204:41 pmRNSSecond Price Monitoring Extn
29th Jul 20204:36 pmRNSPrice Monitoring Extension
15th Jul 20201:04 pmRNSDirector Dealings
13th Jul 20201:29 pmRNSDirector Dealings and Issue of Equity
13th Jul 20201:28 pmRNSGrant of Deferred Share Awards
26th Jun 20202:29 pmRNSDirector Dealings
9th Jun 20207:00 amRNSChronocort Phase 3 data at ENDO Online 2020
29th May 20207:00 amRNSChange of Adviser
30th Apr 20209:05 amRNSSecond Price Monitoring Extn
30th Apr 20209:00 amRNSPrice Monitoring Extension
21st Apr 202010:05 amRNSDirector Dealings and Issue of Equity
16th Apr 20202:23 pmRNSDirector Dealings
15th Apr 20204:41 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSOperational Update
6th Apr 20209:21 amRNSDirector Dealings
1st Apr 20207:00 amRNSChronocort MAA Passes Validation Stage with EMA
30th Mar 20206:18 pmRNSHolding(s) in Company
30th Mar 20203:05 pmEQSHardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further
27th Mar 20205:26 pmRNSHolding(s) in Company
27th Mar 20209:17 amRNSDirector Dealings
27th Mar 20207:00 amRNSUS Licencing Agreement with Eton Pharmaceuticals
26th Mar 20202:05 pmRNSSecond Price Monitoring Extn
26th Mar 20202:00 pmRNSPrice Monitoring Extension
25th Mar 20202:47 pmRNSResult of General Meeting and Issue of Equity
20th Mar 20204:48 pmRNSSecond Price Monitoring Extn
20th Mar 20204:39 pmRNSPrice Monitoring Extension
6th Mar 20204:55 pmRNSResult of Placing and Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.